Short acting GLP-1 receptor agonist (injectable)
Beinaglutide 0.2 mg subcutaneous three times daily
BEIN_SC_0p2MG_TID
Effects across outcomes
Bayesian random effects estimate against the comparator of each analysis (usually placebo), posterior median and 95% credible interval. Green: clearly better; red: clearly worse.
| Condition | Outcome | Window | Versus | Effect (95% CrI) | SUCRA |
|---|---|---|---|---|---|
| Type 2 diabetes (adults) | Level 2 or 3 hypoglycemia (participants) | longest follow-up | Placebo | HR 1.22 (0.28 to 4.69) | 0.55 |
| Type 2 diabetes (adults) | Serious adverse events | longest follow-up | Placebo | HR 0.50 (0.01 to 32.04) | 0.60 |